Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors

Recruiting now · Phase 1

Conditions studied: Liver Cancer, Lung Cancer, Breast Cancer, Colo-rectal Cancer, Brain Tumor, Solid Tumor, Adult, PD1, CTLA4

In brief

Tumor infiltration lymphocytes (TILs) have been harvested from advanced cancer patients and constructed to knockout PD1 gene and express scFvs against both PD1 and CTALA4 and CARs against various antigens, followed by transfusion into the patients. The safety, tolerance, and preliminary clinical efficacy of the TILs will be evaluated.

Key facts

Study ID

NCT04842812

Run by

Second Affiliated Hospital of Guangzhou Medical University

People needed

40

Starts

2021-01-01

Expected to finish

2035-01-01

Last updated by the study team

2024-06-25

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with advanced cancers that failed to current available therapies;
• Life expectancy >12 weeks;
• Adequate heart, lung, liver, kidney functions;
• Available for tumor biopsy or cancerous effusions;
• Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent.

You may not qualify if…

• Had accepted gene therapy before;
• Severe virus infection such as HBV, HCV, HIV, et al; Known HIV positivity;
• Active infectious disease related to bacteria, virus, fungi, et al;
• Other severe diseases that the investigators consider not appropriate;
• Pregnant or lactating women;
• Systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent/kg/day);
• Other conditions that the investigators consider not appropriate.

Where it is running

• Second Affiliated Hospital of Guangzhou Medical University — Guangzhou, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.